

//  
//  
//

## XIII VII II

\*

( )

XIII VII II

/ / / XIII VII II /  
/ / / XIII VII II  
XIII VII II :

( )

XIII VII II :

( )

( )

( )

XIII VII II

)

SPSS

HDL-C LDL-C  
 SGOT LDH CK  
 T C I  
 CRP

( )

± /

( )

/ ± /

/ ± /

VII II

/ ± /

/ ± /

XIII

/ ± /

VII II

XIII

XIII VII II

XIII	VII	II	
/	/	/	
/	/	/	
/	/	/	
/	/	/	
/	/	/	
/	/	/	
/	/	/	

( )

( )

XIII VII II

XIII VII  
Kohler  
( )  
XIII A VII II  
A XIII  
XIII  
Song ( ) Franco  
XIII  
Gilbney Roche ( )  
VII  
Ghaddar ( )  
VII  
VII  
VIIg  
Arg/Lys  
( ) VIIc  
VIIa VIIc VIIg  
XIII VII II  
( )  
XIII  
( )  
Maurar Trumbot  
XIII  
Folsom  
VII  
VII

## REFERENCES

---

---

1. Braunwald E. Heart disease: A Text book of cardiovascular medicine. 5<sup>th</sup> Edition. Saunders Company 1997.
2. Fuster V, Alexander RW, O'roorke RA, Robert R, King SB, Wallens HJJ. Hurst's the Heart. 10<sup>th</sup> Edition. McGraw- Hill 2001. pp: 1065-95.
3. Burtis A, Ashwood-Edward A. Tietz textbook of clinical chemistry. 3<sup>rd</sup> edition, W.B Saunders company 1999. pp: 855-6.
4. Franco RF, Pazin-Filho A, Tavella MH, Simoes VH, Marin-Neto JA, Zago MA. Factor XIII Val 34 Leu and the risk of myocardial. Hematologica. 2000Jan; 85(1):67-71.
5. Roche HM, Gibney MJ. Postprandial coagulation factor VII activity: The effect of monounsaturated fatty acids. Br J Nutr 1997;77(4):537-49.
6. Ghaddar HM, Folsom AR, Aleksic N, Hearne LB, Chambless LE, Morrissey JH, et al. Correlation of factor VIIa Values with factor VII gene polymorphism, Fasting and postprandial triglyceride levels. and subclinical carotid atherosclerosis. Circulation 1998;98(25):2815-21.
7. Holm J, Hillar PA, Erhart L, Berntrop E. Changes in levels of factor VII and protein S after acute myocardial infarction. Thromb Res 1999;96(3):205-12.
8. Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to proposal for explaining the cardioprotective effect observed with the factor XIII 734L mutation. J Biol Chem. 2000;275(27):20627-31.
9. Folsom AR, Wu KK, Rasmussen M, Chambless LE, Aleksic N, Neither RJ. Determinants of population changes in fibrinogen and factor VII over 6 years: The Atherosclerosis Risk in communities (ARIC) study. Atheroscler Thromb Vasc Biol 2000;20(2):601-6.
10. Kohler HP, Schroder V, Chatterjee T, Martini. Factor XIII transglutaminase activity and antigen levels in patients with coronary artery disease investigated by angiography. J Thromb Haemostasis July 2001.
11. K.S. Song. Fibrinogen, factor VII, PA1-1 genotypes and the risk of coronary artery disease. J Thromb Haemostasis 2001 (ISSNO 340- 6245).
12. Lowe GD, Rumley A, McMahan AD, Ford I, O'Reilly DS, Packard CJ. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease Artrioscler Thromb Vasc Biol 2004;24(8):1529-34.

- 
13. Bozzini C , Girelli D, Bernardi F, Ferraresi P, Olivieri O, Pinotti M, et al. Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis. *Thromb Haemost* 2004;92(3):541-9.
  14. Eriksson- Berg M, Deguchi H, Hawe E , Scavini D, Orth-Gamer K, Schenck- Gustafsson K, et al. Influence of factor VII gene polymorphisms and environmental factors on plasma coagulation factor VII concentrations in middle- aged women with and without manifest coronary heart disease. *Thromb Haemost* 2005;93(2):189.